Combioxin SA is a Swiss-based clinical-stage biotechnology company founded in 2015. Combioxin is a recipient of the Swiss FIT SEED program and is a spin-off of LASCCO SA. Combioxin is committed to the development of disruptive treatments for severe infections and has developed CAL02, a novel first-in-class antitoxin agent for the treatment of severe pneumonia. In August 2021, Combioxin entered into a worldwide licensing agreement Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) for the commercial rights to CAL02.
Combioxin is committed to the development of disruptive treatments for severe infections and has developed CAL02. CAL02 neutralizes toxic virulence effectors produced by bacteria. Virulence effectors play a decisive role in the development of long-term, severe and fatal complications to infections. Combioxin carried out a first-in-human clinical trial in patients with severe community-acquired pneumonia. Results were published in The Lancet Infectious Diseases where this study was described “a medical breakthrough”. CAL02 has been characterized as “one step closer to precision medicine for infectious diseases”.
Route de la Corniche 5